医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cover-More Appoints Head of Sales for USA and Canada Travel Insurance Operations

2016年06月29日 PM10:00
このエントリーをはてなブックマークに追加


 

SYDNEY

Cover-More Group (ASX:CVO), a specialist, integrated travel insurance and medical assistance provider, has appointed Mark Linton as Head of Sales for USA and Canada.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160629005594/en/

Mark Linton Cover-More Head of Sales US & Canada (Photo: Business Wire)

Mark Linton Cover-More Head of Sales US & Canada (Photo: Business Wire)

His appointment follows Cover-More’s announcement that their executive Carole Tokody was relocating to New York as CEO, US & Canada and Global Direct to lead their North America and northern hemisphere expansion.

Mark will report directly to Carole Tokody and will be responsible for the sales of travel insurance and ancillary products and services in the US and Canadian markets. Mark’s significant experience includes 15 years with RBC Insurance where he managed a national sales team, maintaining and acquiring numerous large national and regional accounts.

About Cover-More Group

Cover-More Group Limited is a specialist and integrated travel insurance, medical assistance and employee assistance provider. The group listed on the Australian Securities Exchange (ASX) in 2013. Cover-More has the leading market position in Australia—with an approximate 40% share of the national travel insurance market and a growing footprint in India and China as well as a presence in Malaysia, Singapore, New Zealand and the United Kingdom and now the United States.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629005594/en/

CONTACT

For more information:
Pilot PR for Cover-More Group
Limited

Angela Cross, +61412 929 397
angela@pilotpr.com.au

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
  • GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics